Figure 2. Single target and network pharmacology strategies for cancer therapy.

A. Monotherapy for targeting a single, strong oncogene driver leading to cancer cell death. B. Network-based targeting strategies for cancers and inhibition of oncogenic pathways driven by multiple oncoproteins of varying strength (arrow width) can be implemented either by combination therapy with more than one drug (upper panel) or by a single drug with polypharmacology mechanism of action against more than one cancer-relevant target (lower panel).